Ainos Signs MoU For Contract Clinical Trials To Conduct Clinical Study Of Potential New Animal Drug Based On Veldona; Ainos And SIDSCO Jointly Explore VELDONA/Cytoprotein Contract Clinical Trials.
Portfolio Pulse from Benzinga Newsdesk
Ainos has signed a Memorandum of Understanding (MoU) with SIDSCO for contract clinical trials to conduct a study of a potential new animal drug based on VELDONA. The upcoming clinical study will investigate VELDONA's safe use and efficacy for the treatment of feline chronic gingivostomatitis (FCGS) via oral mucosal administration.
November 06, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ainos' partnership with SIDSCO for clinical trials of a new animal drug based on VELDONA could potentially impact AIMD's stock positively if the trials are successful.
The partnership between Ainos and SIDSCO for the development of a new animal drug based on VELDONA could potentially lead to a new revenue stream for Ainos, which could positively impact AIMD's stock. However, this is contingent on the success of the clinical trials and the subsequent approval of the drug.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80